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The psoralen-related compound, 4,6,4′-trimethylangelicin (TMA) potentiates the
cAMP/PKA-dependent activation of WT-CFTR and rescues F508del-CFTR-dependent
chloride secretion in both primary and secondary airway cells homozygous for the
F508del mutation. We recently demonstrated that TMA, like lumacaftor (VX-809),
stabilizes the first membrane-spanning domain (MSD1) and enhances the interface
between NBD1 and ICL4 (MSD2). TMA also demonstrated anti-inflammatory properties,
via reduction of IL-8 expression, thus making TMA a promising agent for treatment of
cystic fibrosis. Unfortunately, TMA was also found to display potential phototoxicity and
mutagenicity, despite the fact that photo-reactivity is absent when the compound is not
directly irradiated with UVA light. Due to concerns about these toxic effects, new TMA
analogs, characterized by identical or better activity profiles and minimized or reduced
side effects, were synthesized by modifying specific structural features on the TMA
scaffold, thus generating compounds with no mutagenicity and phototoxicity. Among
these compounds, we found TMA analogs which maintained the potentiation activity of
CFTR in FRT-YFP-G551D cells. Nanomolar concentrations of these analogs significantly
rescued F508del CFTR-dependent chloride efflux in FRT-YFP-F508del, HEK-293 and
CF bronchial epithelial cells. We then investigated the ability of TMA analogs to enhance
the stable expression of varying CFTR truncation mutants in HEK-293 cells, with the aim
of studying the mechanism of their corrector activity. Not surprisingly, MSD1 was the
smallest domain stabilized by TMA analogs, as previously observed for TMA. Moreover,
we found that TMA analogs were not effective on F508del-CFTR protein which was
already stabilized by a second-site mutation at the NBD1-ICL4 interface. Altogether, our
findings demonstrate that these TMA analogs mediate correction by modifying MSD1
and indirectly stabilizing the interface between NBD1 and CL4.
Keywords: trimethylangelicin, cystic fibrosis, cystic fibrosis transmembrane conductance regulator, correctors,
potentiators
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INTRODUCTION
Cystic fibrosis (CF) is an autosomal recessive genetic disease
caused by mutations in the cystic fibrosis transmembrane
conductance regulator (CFTR) gene. Over 2,000 sequence
variations have been reported so far, many of which have
been defined as causative (see the Cystic Fibrosis Mutation
Database of the Cystic Fibrosis Gene Analysis Consortium1)
(Riordan et al., 1989; Gadsby et al., 2006). CFTR is an
ABC transporter, containing two membrane-spanning domains
(MSD1 and MSD2), with a total of four intracellular loops
(ICL1-4), two nucleotide-binding domains (NBD1 and NBD2),
and a regulatory domain (R) (Riordan, 2008). CFTR activation
requires ATP binding to the interface between NBD1 and NBD2,
in addition to protein kinase A (PKA)-mediated phosphorylation
of the R domain (Cheng et al., 1991; Berger et al., 2005). CFTR
acts as a chloride channel expressed on the apical membrane of
epithelial cells, where its function is essential for maintenance
of salt and fluid homeostasis. The deletion of phenylalanine at
position 508 (F508del), the most common disease-causing CFTR
mutation, is located in NBD1 and exists in∼90% of patient alleles
(Veit et al., 2016; Mijnders et al., 2017). F508del is a class II
CF mutation, which results in a folding defect in the full-length
F508del-CFTR, which is mediated through the NBD1:ICL4
interface. Improper folding leads to premature degradation by
the ubiquitin-proteasome system. This degradation, due to lack
of cell surface CFTR expression, then causes ionic imbalance
and aberrant fluid homeostasis at epithelial surfaces in the
lung, thus producing thick mucus and causing impairment of
mucociliary clearance, ultimately predisposing the patients to
bacterial infections, inflammation and impaired lung function
(Boucher, 2007).
Small-molecule compounds, which are known to modulate
either defective F508del-CFTR folding and processing
(correctors) or channel gating (potentiators), are promising
therapeutic strategies for treatment of CF by targeting the
underlying defects in CFTR protein (Pedemonte et al., 2005).
CFTR correctors increase the cell-surface expression of F508del-
CFTR either indirectly, by acting as proteostasis regulators
and thus modulating the activity of proteins involved in
folding, degradation or trafficking of F508del-CFTR (Hanrahan
et al., 2013), or directly, through binding as pharmacological
chaperones to F508del-CFTR (Okiyoneda et al., 2013). Unlike
conventional correctors needing several hours to effectively
rescue protein expression, potentiators interact directly
with CFTR, to rapidly increase CFTR channel activation
by either ATP-dependent (Hwang and Sheppard, 2009) or
ATP-independent (Eckford et al., 2012) mechanisms.
KALYDECOTM, developed by Vertex Pharmaceuticals and
also known as ivacaftor (VX-770), is a small-size potentiator
approved for treatment of patients carrying the CFTR class
III mutation G551D, along with nine other rare ‘gating’ defect
mutations (Van Goor et al., 2009, 2014; Yu et al., 2012). The
two additional correctors lumacaftor (VX-809) and Tezacaftor
(VX-661), also developed by Vertex Pharmaceuticals, promote
1www.genet.sickkids.on.ca/cftr/
protein stability and forward trafficking of F508del-CFTR to cell
surface (Van Goor et al., 2009, 2011; Hanrahan et al., 2017).
ORKAMBITM has recently emerged as the first combination
therapy. In combination with ivacaftor, lumacaftor was found
to significantly enhance the functional activity of F508del-CFTR
in pre-clinical studies of primary bronchial cells and rectal
biopsy-derived organoids (Van Goor et al., 2011; Dekkers et al.,
2013).
The mechanism of action of lumacaftor (recently categorized
as a Class I corrector) has been investigated by several groups
(Loo et al., 2013; Ren et al., 2013; Laselva et al., 2016, 2018;
Hudson et al., 2017; Loo and Clarke, 2017). Previous studies using
isolated domains of CFTR showed that the N-terminal domain
of CFTR (i.e., MSD1) was important for the stabilizing effect
of lumacaftor (Loo et al., 2013; Ren et al., 2013; Laselva et al.,
2016). In the context of the full-length mutant protein F508del-
CFTR, a secondary “rescue” mutation that partially compensates
for defective interaction of NBD1 and ICL4, namely R1070W,
partially abrogated the correction mediated by lumacaftor; thus
arguing that lumacaftor mediates its correction via allosteric
effects on this interface (He et al., 2013; Okiyoneda et al., 2013;
Laselva et al., 2018). As yet, it is not clear how interaction of
lumacaftor at MSD1 mediates such changes in inter-domain
interaction. Okiyoneda et al. (2013) proposed a scheme wherein
lumacaftor and other correctors that act via this mechanism are
described as Class I correctors.
It has been more recently reported that prolonged treatment
with the potentiator ivacaftor induces a dose-dependent reversal
of the lumacaftor-mediated F508del-CFTR rescue in human
bronchial epithelial cultures. An increased turnover rate at the
cell surface of rescued F508del-CFTR, and the resulting decreased
stability, have been proposed as the underlying mechanisms
(Cholon et al., 2014; Veit et al., 2014).
These findings suggest that use of compounds with dual
activity (i.e., corrector and potentiator) may be an appealing
therapeutic perspective for CF treatment.
Previous studies showed that the psoralen-related compound
4,6,4′-trimethylangelicin (TMA) potentiates cAMP/PKA-
dependent activation of WT-CFTR (Tamanini et al., 2011)
and rescues F508del-CFTR-dependent chloride secretion in
both primary and secondary airway cells homozygous for the
F508del mutation (Favia et al., 2014; Abbattiscianni et al.,
2016). We recently demonstrated that TMA, like lumacaftor,
stabilizes the first membrane-spanning domain (MSD1) of CFTR
(Laselva et al., 2016) and enhances the interface between NBD1
and ICL4 (MSD2) (Laselva et al., 2018) The inhibitory effect
on Pseudomonas aeruginosa-dependent IL-8 transcription at
nanomolar concentrations in CF-derived bronchial epithelial
cells (Tamanini et al., 2011) is another interesting property
of TMA. Therefore, TMA appears to act as a triple-acting
compound, exhibiting anti-inflammatory activity, in addition to
corrector and potentiator properties. TMA was designated by
EMA as an Orphan Drug for the treatment of cystic fibrosis with
the code EU/3/13/1137.
Despite these promising properties, TMA has some potential
drawbacks, such as mutagenicity (Bianchi et al., 1990) and photo-
reactivity toward DNA pyrimidine bases (Bordin et al., 1991),
Frontiers in Pharmacology | www.frontiersin.org 2 July 2018 | Volume 9 | Article 719
fphar-09-00719 July 2, 2018 Time: 15:32 # 3
Laselva et al. TMA Analogs and CFTR Modulation
albeit the latter is not observed when the compound is not
directly irradiated with UVA light.
Due to our expertise in the field of furocoumarin derivatives
with anti-inflammatory properties (Borgatti et al., 2011; Marzaro
et al., 2013, 2015), we designed a small library of TMA analogs
to help determine whether different properties of TMA are
dependent upon specific functional groups present on the
scaffold of parent compound, and to identify which structural
determinants possess biological activity (Supplementary
Figure S1). Furthermore, we aimed to establish whether the
side effects could be reduced or even abolished through specific
structural modifications, which do not impair the biological
properties of TMA.
The first series of derivatives showed good anti-inflammatory
properties, via NF-κB inhibition (Lampronti et al., 2017), and
paved the way to identifying two interesting compounds, 4,7,4′-
trimethylallopsoralen (ALLO) and 4,6-dimethylangelicin (DMA)
(Supplementary Figure S1), which deserve further investigation
into their mechanism of action, although these two isomers
showed residual photoactivity and mutagenicity.
A second series was designed and synthesized, in an effort
to abolish or minimize these side effects (Marzaro et al., 2018).
Three additional non-mutagenic compounds were subsequently
be identified: 4-isopropyl-6-ethyl-4′-methylangelicin (IPEMA),
4-propyl-6-ethyl-4′-methylangelicin (PEMA) and 4-isopropyl-
6,4′-dimethylangelicin (IPDMA) (Supplementary Figure S1).
Interestingly, IPEMA lacks photoreactivity, whilst PEMA and
IPDMA have some residual photoreactive potential under direct
UVA irradiation.
Therefore, the aim of this study was to explore the effect of
TMA analogs on CFTR function and determine their mechanism
of action.
MATERIALS AND METHODS
Compounds
lumacaftor and ivacaftor were obtained by Selleckchem
(United States), TMA and TMA analogs were partly synthesized
as previously described (Guiotto et al., 1984, 1995; Marzaro et al.,
2018) and partly belong to the collection of the Organic Synthesis
Lab (Department of Pharmaceutical Sciences, University of
Padova). DMA was newly synthesized as described in the
Supplementary Material. TMA and TMA analogs were dissolved
in DMSO at a final concentration of 200 µM (stock solution),
whereas lumacaftor and ivacaftor were dissolved in DMSO at a
final concentration of 10 mM.
Cell Lines
Fischer Rat Thyroid (FRT) epithelial cells, stably co-expressing
human F508del (FRT-F508del) or G551D (FRT-G551D) CFTR
and the high-sensitivity halide-sensing green fluorescent analog
yellow fluorescent protein (HS-YFP) YFP-H148Q/I152L were a
generous gift from L. J. Galietta (Telethon Institute of Genetics
and Medicine, Pozzuoli, Italy). Cells were grown in Coon’s
Modified Ham’s F-12 media plus 10% fetal bovine serum (FBS),
L-glutamine, and penicillin/streptomycin at 37◦C under 5%
CO2 (Pedemonte et al., 2010). CuFi-1 cells, a generous gift of
A. Klingelhutz, P. Karp, and J. Zabner (University of Iowa,
Iowa City), is a human bronchial epithelial cell line derived
from a CF patient (CuFi-1, F508del/F508del CFTR mutant
genotype) and transformed by reverse transcriptase component
of telomerase (hTERT), human papillomavirus type 16 (HPV-16)
E6 and E7 genes (Zabner et al., 2003). These cells were
grown on human placental collagen type VI (Sigma, St. Louis,
MO, United States) coated flasks in BEGM medium (Cambrex
Bio Science Walkersville, Walkersville, MD, United States), as
described (Zabner et al., 2003).
CFBE41o- cells, stably overexpressing F508del-CFTR
(CFBE41o-F508del) homozygous for the F508del allele
(F508del/F508del) (a generous gift from J. P. Clancy, University
of Cincinnati, Children’s Hospital Medical Center, Cincinnati,
OH, United States) are human bronchial epithelial cells,
grown in complete media (EMEM, 10% FBS, L-glutamine,
and penicillin/streptomycin) in the presence of 2 µg/ml
puromycin positive selection. Cells were routinely grown
on flasks coated with an extracellular matrix containing
fibronectin/vitrogen/BSA, at 37◦C under 5% CO2.
Human Embryonic Kidney (HEK)-293 GripTite cells (HEK)
from Dr. Daniela Rotin (Hospital for Sick Children, Toronto,
ON, Canada) were maintained in DMEM (Wisent, St-Bruno,
QC, Canada) supplemented with non-essential amino acids
(Life Technologies, Waltham, MA, United States) and 10% FBS
(at 37◦C with 5% CO2 (HEPA incubator, Thermo Electron
Corporation) and processed as previously described (D’Antonio
et al., 2013; Molinski et al., 2015). Transient transfections
were performed using PolyFect Transfection Reagent (Qiagen,
Hilden, Germany), according to the manufacturer’s protocol,
as previously described (Molinski et al., 2015; Laselva et al.,
2016).
Fluorescence Measurements of Iodide
Influx
Iodide influx was measured in FRT-YFP F508del cells, as
described elsewhere (Pedemonte et al., 2005) from the kinetics
of YFP fluorescence decrease following addition of extracellular
iodide in the presence of CFTR stimulating cocktail. Cells were
seeded on round glass coverslips and pre-incubated for 48 h
with vehicle, TMA, TMA analogs or lumacaftor. At the time
of assay, cells were washed in Dulbecco’s PBS (in mM: 137
NaCl, 2.7 KCl, 8.1 Na2HPO4, 1.5 KH2PO4, 1 CaCl2, and 0.5
MgCl2, pH 7.4) and subsequently incubated with stimulation
cocktail (20 µM forskolin and 5 µM ivacaftor) in presence
or absence of 10 µM CFTR inhibitor, CFTRInh-172 (Sigma),
for 30 min. FRT-G551D cells were washed as indicated above
and incubated with stimulation cocktail (20 µM forskolin and
vehicle or genistein, ivacaftor, TMA or TMA analogs) in the
presence or absence of CFTRInh-172 for 30 min. The cover slips
were then transferred onto a Nikon TMD inverted microscope,
through a Nikon Fluor 40 objective, and signal was acquired
with a Hamamatsu C2400–97 charge-coupled intensified video
camera at a rate of 1 frame/3 s. Fluorescence coming from
each single cell of at least five cells per field was analyzed by a
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customized software (Spin, Vicenza, Italy). Results are presented
as transformed data to obtain the percentage signal variation
[1F(t)] relative to the time of addition of stimulus, according
to the equation: 1F(t) = 100[F(t) – F(0)]/F(0), where Ft and
F0 are the fluorescence values at the time t, and at the time of
iodide addition, respectively. YFP fluorescence decay rate was
calculated by fitting fluorescence data of time courses by means
of an exponential function. CFTR activity was calculated as the
difference between YFP fluorescence decay rate in absence or in
the presence of CFTRInh-172. The assay of each sample consisted
of continuous 120-s fluorescence readings with injection, 40 s
before and 80 s after, of iodide-rich Dulbecco’s PBS (in mM:
137 NaI, 2.7 KCl, 8.1 Na2HPO4, 1.5 KH2PO4, 1 CaCl2, and 0.5
MgCl2, pH 7.4), to reach a final iodide concentration of 50 mM,
as described (Favia et al., 2014).
CFTR-Dependent Chloride Efflux in
Bronchial Epithelial Cells
Cystic fibrosis transmembrane conductance regulator function
was assessed in CuFi-1 and CFBE41o-F508del cells by single-
cell fluorescence imaging, using the potential-sensitive probe
DiSBAC2(3) (Molecular Probes, Eugene, OR, United States) as
previously reported (Dechecchi et al., 2007). CFTR dependent
Cl− channel activity was stimulated by a cAMP elevating cocktail
consisting of 20 µM forskolin plus 5 µM ivacaftor. CFTRInh-
172 was added to a final concentration of 10 µM. Briefly,
cells grown on coated round glass coverslips were washed in a
Cl− containing solution (mM): 101 Na++, 114 Cl−, 5 K+, 2
Ca2+, 2 Mg2+, 50 mannitol, 5 glucose, 5 HEPES-Tris, pH 7.4,
mounted in a perfusion chamber (Medical System, Baltimore,
MD, United States), and perfused for 10–15 min at 25◦C with
a Cl− free solution (mM): 101 Na+, 106 gluconate, 14 acetate,
5 K+, 2 Ca2+, 2 Mg2+, 50 mannitol, 5 glucose, 5 HEPES-Tris,
pH 7.4, containing 100 nM DiSBAC2(3). The time courses were
performed at 25◦C and a baseline signal was acquired before the
addition of the stimulus. Results are presented as transformed
data to obtain the percentage signal variation [1F(t)] relative
to the time of stimulus addition according to the equation:
1F(t) = 100[F(t)–F(0)]/F(0), where Ft and F0 are the fluorescence
values at the time t and at the time of stimulus addition,
respectively.
CFTR Channel Function Using
Membrane Depolarization Assay
Cystic fibrosis transmembrane conductance regulator functional
measurements were performed with fluorometric imaging plate
reader (FLIPR) membrane depolarization assay in HEK-293 cells,
using the blue membrane potential dye (Molecular Devices,
San Jose, CA, United States) which can detect changes in
transmembrane potential.
HEK-293 cells stably overexpressing F508del-CFTR or HEK-
293 cells transiently transfected with F508del/R1070W construct,
were grown to 100% confluence in 96-well plates (black, flat
bottom; Costar) and treated for 24 h with 3 µM VX-809, 200
nM TMA, 200 nM IPEMA, 200 nM IPDMA, 200 nM DMA,
200 nM ALLO or DMSO. Cells were washed with PBS and
the blue membrane potential dye, dissolved in chloride-free
buffer containing 136 mM sodium gluconate, 3 mM potassium
gluconate, 10 mM glucose, 20 mM HEPES, pH 7.35, 300
mOsm, at a concentration of 0.5 mg/ml, was added to the
cells for 1 h at 37◦C (Laselva et al., 2016; Ahmadi et al.,
2017; Molinski et al., 2017). The plate was then read in a
fluorescence plate reader (SpectraMax i3; Molecular Devices) at
37◦C. After reading baseline fluorescence, CFTR was stimulated
with the cAMP agonist forskolin (10µM; Sigma-Aldrich) and the
potentiator ivacaftor (1 µM; Selleck Chemicals). CFTR-mediated
depolarization of membrane was detected as an increase in
fluorescence, whilst repolarization or hyperpolarization was
detected as a decrease (Maitra et al., 2013; Ahmadi et al., 2017). To
terminate the assay, CFTR-specific inhibitor 172 (CFTRinh-172,
10 µM; Cystic Fibrosis Foundation Therapeutics) was added to
all wells. Changes in membrane potential were normalized to
fluorescence before addition of agonist (forskolin).
Western Blotting
HEK-293 expressing F508del-CFTR or transiently transfected
with F508del/R1070W-CFTR, were grown to 100% confluence
FIGURE 1 | Effect of TMA analogs on CFTR-dependent chloride efflux in
FRT-G551D cells. FRT-YFP-G551D cells, grown on round glass coverslips,
were treated for 30 min with vehicle alone or genistein (50 µM), ivacaftor (5
µM), TMA or its analogs (200 nM), before the fluorescence assay.
CFTR-dependent chloride efflux was assayed by single-cell fluorescence
imaging analysis of YFP fluorescence quenching by iodide, stimulated by
forskolin (20 µM), in the presence or absence of CFTRInh-172 (10 µM). The
assay of each sample consisted of a continuous 120-s fluorescence reading
with 40 s before and 80 s after injection of the iodide-rich Dulbecco’s PBS.
Results are presented as transformed data, to obtain the percentage signal
variation [1F(t)] relative to the time of addition of iodide, according to the
equation: 1F(t) = 100[F(t)–F(0)]/F(0), where Ft and F0 are the fluorescence
values at the time t and at the time of addition of iodide, respectively. YFP
fluorescence decay rate was calculated by fitting with an exponential function
fluorescence data of time course. CFTR activity was obtained by the
difference between YFP fluorescence decay rate in absence and in the
presence of CFTRInh-172. Fluorescence coming from each single cell of at
least five cells per field was recorded. Each bar corresponds to the
mean ± SEM of data points coming from at least three different experiments.
Statistical comparisons were made using non-parametric Mann–Whitney U
test (∗P < 0.05, ∗∗P < 0.01, and ∗∗∗ P < 0.001).
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in 24-well plates (Costar) and treated for 24 h with 3 µM
lumacaftor, 200 nM TMA, 200 nM IPEMA, 200 nM IPDMA,
200 nM DMA, 200 nM ALLO or DMSO. Cells were
then lyzed in modified radioimmunoprecipitation assay buffer
(50 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, pH 7.4,
0.2% SDS, and 0.1% Triton X-100) containing a protease
inhibitor cocktail (Roche) for 10 min, and the soluble fractions
were analyzed by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) on 6% Tris-Glycine gels (Life
Technologies). After electrophoresis, proteins were transferred
to nitrocellulose membranes (Bio-Rad) and incubated in
5% milk. CFTR bands were detected with human CFTR
specific murine mAb 596 (1:10,000; University of North
Carolina at Chapel Hill). Relative expression level of CFTR
FIGURE 2 | Effect of TMA analogs on CFTR-dependent chloride efflux in
FRT-F508del cells. FRT-YFP-F508del cells, grown on round glass coverslip,
were treated for 48 h with vehicle alone or lumacaftor (5 µM), TMA or its
analogs (200 nM). CFTR function was assayed at 48 h as indicated in the
Figure 1 legend, in the presence of forskolin (20 µM) plus ivacaftor (5 µM).
(A) Representative traces showing iodide influx in control conditions (vehicle)
or after 48 h incubation with ALLO. (B) Summary of data from different TMA
analogs compared to TMA and lumacaftor. CFTR activity was calculated as
indicated in Figure 1 legend. Each bar represents the mean ± SEM of at least
three different experiments. Dashed line corresponds to cells treated with
vehicle. Statistical comparisons were made using non-parametric
Mann–Whitney U test (∗P < 0.05, ∗∗P < 0.01, and ∗∗∗P < 0.001).
proteins were quantified by densitometry of immunoblots,
using ImageJ software version 1.46 (National Institutes of
Health).
CFTR Steady-State Levels
Steady-state levels of CFTR truncation fragments were assayed
with Western Blot analysis. HEK cells were transiently transfected
with 1NBD2 (containing residues 1–1172), 1R (700–835 del)
MSD1-NBD1-R (containing residues 1–845), MSD1 (containing
1–380), MSD1-D373X (containing residues 1–372) and MSD2
(containing residues 837–1196). Transient transfections were
performed using PolyFect Transfection Reagent (Qiagen,
Hilden, Germany), according to the manufacturer’s protocol,
as previously described (Molinski et al., 2015; Laselva et al.,
2016, 2018). After 18 h of transfection, the cells were treated
with 3 µM lumacaftor, 200 nM TMA, 200 nM IPEMA, 200
nM IPDMA, 200 nM DMA, 200 nM ALLO or vehicle control
(DMSO) and 24 h after correction the cells were lyzed in
modified radioimmunoprecipitation assay buffer (50 mM
Tris-HCl, 150 mM NaCl, 1 mM EDTA, pH 7.4, 0.2% SDS,
and 0.1% Triton X-100) containing a protease inhibitor
cocktail (Roche) for 10 min. The soluble fractions were
then analyzed by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) on 6% (1NBD2 and1R) or 4–12%
Tris-Glycine gels (Life Technologies). After electrophoresis,
proteins were transferred to nitrocellulose membranes (Bio-Rad)
and incubated in 5% milk. CFTR bands then were detected
with human CFTR-MSD1-specific murine mAb MM13-4
(1:10,000; EMD Millipore, Billerica, MA, United States) or
with monoclonal antibody A52 for MSD2 (1:1,000) (Dr. David
Clarke, University of Toronto) (Loo et al., 2013; Laselva et al.,
2016).
Statistics
Statistical analysis was carried out with non-parametric Mann–
Whitney U test and, one-way ANOVA, using Prism 7.0
Software (GraphPad Software, San Diego, CA, United States).
One-way/two-way analyses of variance were conducted, when
appropriate (∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001, and
∗∗∗∗P < 0.0001).
TABLE 1 | Potency and efficacy of TMA analogs as correctors of F508del CFTR in
FRT-YFP F508del cells.
TMA
analog
EC50 (nM) CI (nM) Maximum effect
(CFTR activity)
CI (CFTR
activity)
ALLO 156 76 0.626 0.11
DMA 55 31 0.448 0.05
IPEMA 40 20 0.523 0.06
IPDMA 164 83 1.434 0.32
FRT-YFP F508del cells were treated with increasing concentrations from 50 to 500
nM of selected TMA analogs: ALLO, DMA, IPEMA, and IPDMA. CFTR activity was
measured as indicated in “Materials and Methods” section. Data obtained from at
least three different experiments were fitted by a rectangular hyperbola with Graph
Pad prism 6.0 in order to obtain potency (EC50) and efficacy (Maximum effect).
CI = 95% confidence interval.
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RESULTS
Effect of TMA Analogs on
FRT-YFP-G551D Cells
Some linear and angular furocoumarins, such as 5- or 8-MOP
and angelicin, have been shown to act as potentiators of CFTR-
mediated chloride transport (Devor et al., 1997). We recently
found that also TMA potentiates the cAMP/PKA-dependent
activation of wild-type or surface expressed F508del-CFTR
(Tamanini et al., 2011). Therefore, the effect of acute incubation
with these new TMA analogs on class III CFTR mutations was
tested in FRT-YFP-G551D cells, in comparison with genistein,
ivacaftor, and TMA. As reported in Figure 1, the analogs DMA,
ALLO, IPEMA, PEMA, and IPDMA significantly potentiated
G551D-CFTR-dependent chloride activity. DMA, ALLO, PEMA,
and IPDMA were comparable to genistein. IPEMA was the most
effective, although its efficacy was lower than that of TMA or
ivacaftor. These results indicate that the structural modifications
on the drug scaffold maintain TMA’s potentiating activity of
CFTR.
Effect of TMA Analogs on
FRT-YFP-F508del Cells
It was previously shown that TMA rescues surface expression
and channel function of F508del-CFTR in primary and secondary
human bronchial epithelial cells (Favia et al., 2014).
To explore the role of these analogs as correctors of F508del-
CFTR, we first performed the analysis of CFTR-mediated
chloride transport in the model of FRT-YFP-F508del cells, after
long-term incubation with different compounds. TMA and TMA
analogs (200 nM), lumacaftor−809 (5µM) or vehicle were added
to FRT-YFP-F508del cells for 48 h at 37◦C, and correction of
F508del-CFTR function was assessed by measuring the decrease
of YFP fluorescence upon addition of extracellular iodide and
with the activating cocktail (20 µM forskolin, and 5 µM
ivacaftor). As shown by a representative experiment, correction
of F508del-CFTR resulted in larger reduction of YFP fluorescence
induced by increased iodide influx compared to cells treated
with vehicle alone. The CFTR-dependent decrease of YFP-
fluorescence signal was verified by traces obtained in the presence
of CFTRInh-172 (Figure 2A). The TMA analogs (Supplementary
Figure S1) were compared to TMA and lumacaftor. Figure 2B
shows that among these compounds, five TMA analogs (DMA,
ALLO, IPEMA, PEMA, and IPDMA) significantly rescued
F508del-CFTR-dependent activity in FRT-YFP-F508del cells,
after 48 h pre-incubation at 37◦C. In particular, DMA, ALLO,
IPEMA, and IPDMA were the most effective correctors of
F508del-CFTR, although to a lesser extent than TMA or
lumacaftor.
We hence selected these TMA analogs and performed dose-
response experiments, in order to evaluate their potency and
efficacy. Cells were treated for 48 h at 37◦C with vehicle alone,
or different concentrations (50–500 nM) of TMA analogs. Values
FIGURE 3 | Effect of treatment combinations in rescuing F508del CFTR function in FRT-F508del cells. FRT-YFP-F508del cells, grown on round glass coverslips,
were treated for 48 h with vehicle alone or lumacaftor (5 µM), TMA (200 nM), DMA (100 nM) (A), ALLO (100 nM) (B), IPEMA (100 nM) (C), IPDMA (100 nM) (D)
alone, or in combination with TMA or lumacaftor. CFTR-dependent chloride efflux was assayed as indicated in Figure 1 legend. CFTR activity was calculated as
indicated in Figure 1 legend. Each bar corresponds to the mean ± SEM of at least three different experiments. Statistical comparisons were made using
non-parametric Mann–Whitney U test (∗P < 0.05, ∗∗P < 0.01, and ∗∗∗P < 0.001).
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of CFTR activity in cells treated with different concentrations of
TMA analogs were fitted by a rectangular hyperbola and EC50
and maximum effect were calculated.
As shown in Table 1, DMA, ALLO, IPEMA, and IPDMA were
very potent correctors, being EC50 values in the nanomolar range.
IPEMA and DMA were more powerful than ALLO and IPDMA.
Among these analogs, IPDMA was the most effective, since CFTR
activity was about fivefold higher than that of untreated cells.
Effect of TMA Analogs in Combination
With TMA or Lumacaftor on FRT-YFP
F508del Cells
Ideally, the combination of a potentiator with multiple correctors,
each with a different mechanism of action should be seen
as an especially promising approach, since it should promote
further improvement in drug efficacy and clinical benefit for
CF patients. In order to evaluate a possible additive effect of
TMA analogs with correctors lumacaftor and TMA, we treated
FRT-YFP F508del cells with TMA analogs DMA, ALLO, IPEMA,
and IPDMA (100 nM) alone or in combination with TMA
or lumacaftor (Figures 3A–D). None of these TMA analogs
improved the correcting effect of lumacaftor or TMA (Figure 3),
thus suggesting that lumacaftor, TMA and TMA analogs share a
similar mechanism of action related to the rescue F508del-CFTR
function. These results correlate with data previously observed
for TMA and lumacaftor (Favia et al., 2014; Laselva et al., 2016).
Notably, the combination of TMA with the structurally related
analogs DMA or ALLO (Figures 3A,B), significantly reduced the
CFTR activity compared to TMA alone.
Effect of TMA Analogs on CF Human
Bronchial Epithelial Cells
The corrector activity was earlier found to be strongly dependent
on cell background, with the extreme case of many compounds
working only on a single cell type (Pedemonte et al., 2010).
TMA rescued F508del-CFTR-dependent chloride secretion and
cell surface expression in both primary and secondary airway
cell monolayers homozygous for F508del mutation (Favia et al.,
2014), thus indicating that the correcting effect of TMA is not
influenced by cell background. The effect of TMA analogs was
tested in CF human bronchial epithelial cells CuFi-1 (Figure 4A)
and CFBE41o-F508del (Figures 4B,C), incubated for 48 h at
37◦C in the presence of vehicle alone or lumacaftor or TMA
or analogs. Data were then analyzed by single cell digital
imaging using the membrane potential-sensitive fluorescence
probe DiSBAC2(3) (Dechecchi et al., 2007). As shown in Figure 4,
activation of CFTR increased the DiSBAC2(3) fluorescence in CF
cells treated with correctors, as a function associated with cell
membrane depolarization in the presence of a Cl− gradient. The
DiSBAC2(3) fluorescence decrease obtained by CFTRInh-172
further confirms the specificity of this CFTR-mediated chloride
eﬄux measured in this functional assay. Similar to lumacaftor
and TMA, TMA analogs DMA, ALLO (Figures 4A,B), IPEMA,
and IPDMA (Figure 4C) rescued F508del-CFTR function in CF
human bronchial epithelial cells.
FIGURE 4 | Effect of selected TMA analogs DMA, ALLO, IPEMA, and IPDMA
on CFTR-dependent chloride efflux in CF human bronchial cells.
CFTR-dependent chloride function was assayed by single cell fluorescence
imaging, using a membrane-potential sensitive dye. (A) CuFi-1 cells grown on
round glass coverslips were treated for 48 h with vehicle or lumacaftor (5 µM),
TMA (200 nM) or DMA (200 nM) or ALLO (200 nM) and then mounted on the
perfusion chamber and perfused with Cl− free solution containing DiSBAC2(3)
to allow the equilibration of the dye within the cell membrane. The arrows
indicate the time of the addition of the stimulus: forskolin (20 µM) and
ivacaftor (5 µM) or the CFTRInh-172 (10 µM). Fluorescence signal from each
single cell of at least five cells per field was analyzed and represented by time
course tracings. Data represent the mean ± SEM of the relative fluorescence
collected from all the cells in the field. A representative of four independent
experiments is shown. (B) CFBE41o-F508del cells, were treated as indicated
in (A). A representative of three independent experiments is shown.
(C) CFBE41o-F508del cells were treated for 48 h with vehicle or lumacaftor (5
µM), TMA (200 nM) or IPDMA (200 nM) or IPEMA (200 nM). A representative
of four independent experiments is shown.
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The Corrector Activity of TMA Analogs in
HEK-293 Cells
Previous studies showed that both lumacaftor and TMA
partially rescued the processing defect of F508del-CFTR, such
that the immature core-glycosylated (Band B) form of the
protein both acquired complex-glycosylation (Band C in SDS-
PAGE) and exhibited partial function at the plasma membrane
(Van Goor et al., 2009; Favia et al., 2014). We recently
demonstrated that both modulators rescued F508del-CFTR
through stabilization of the first membrane spanning domain
(MSD1) (Laselva et al., 2016). We now were capable to identify
the mechanism of action of these novel TMA analogs, as
previously described.
We first performed functional measurements using the FLIPR
membrane depolarization assay in HEK-293 cells (Laselva et al.,
2016; Ahmadi et al., 2017), showing that TMA analogs (200
nM) rescued F508del-CFTR-dependent chloride conductance in
HEK-293 cells incubated for 24 h at 37◦C (Figures 5A,B). These
TMA analogs were also capable to increase abundance of both the
immature (Band B) and mature bands (Band C) of F508del-CFTR
(Figures 5C,D).
TMA Analogs Stabilize N-Terminal CFTR
Fragments That Contain MSD1
To identify the region(s) of CFTR required for corrector activity
of these TMA analogs, we then expressed different lengths CFTR
fragments in HEK-293 cells (Figure 6).
Cells were treated for 24 h at 37◦C with 3 µM lumacaftor,
200 nM TMA, or 200 nM TMA analogs (IPEMA, IPDMA, DMA,
ALLO). Like what has been observed with lumacaftor and TMA,
pre-incubation with all TMA analogs promoted enhanced steady
state levels of all CFTR fragments including MSD1 residues (1–
380). TMA analogs did not increase the steady-state abundance
of MSD2 (Figure 6C), thus suggesting that these TMA analogs
interact with and stabilize the MSD1.
Stabilization of NBD1/ICL4 Interface in
F508del Is Modified Correction by TMA
Analogs
Substitution of native arginine with a tryptophan at position 1070
in the F508del-CFTR protein (i.e., R1070W in ICL4) was shown
to partially repair the assembly defect in the full-length mutant
FIGURE 5 | TMA analogs rescued F508del-CFTR similarly to lumacaftor and TMA. (A) Functional analysis in HEK cells stably transfected with F508del-CFTR, using
the fluorometric imaging plate reader membrane depolarization assay, in the presence or absence of correctors. Following 5 min baseline measurement, CFTR was
activated by forskolin (FSK) (1 µM). After 5 min incubation, a CFTR potentiator (ivacaftor, 1 µM) was added for 10 min. CFTR inhibitor (CFTRinh-172, 10 µM) was
then added to deactivate CFTR. (B) Shows the mean (±SEM) of maximal activation of CFTR after stimulation by FSK and ivacaftor (n = 3). Statistical comparisons
were made using one-way ANOVA test (∗∗P < 0.01 and ∗∗∗∗P < 0.0001). (C) HEK F508del-CFTR stable transfected cells were treated in the presence or absence
of correctors for 24 h at 37◦C. C, mature complex-glycosylated CFTR; B, immature core-glycosylated CFTR. (D) Bar graphs show the mean (±SEM) of ratio
C/(C + B) of CFTR (n = 3). Statistical comparisons were made using one-way ANOVA test (∗P < 0.05, ∗∗P < 0.01, and ∗∗∗P < 0.001).
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FIGURE 6 | TMA analogs stabilize MSD1 of CFTR. (A) Graphical image of the CFTR structure. (B) Domain boundaries of CFTR fragments used in this study. (C) The
effect of lumacaftor (3 µM), TMA (200 nM), DMA (200 nM), ALLO (200 nM), IPEMA (200 nM), and IPDMA (200 nM) on the abundance of CFTR fragments. Data are
representative of three experiments. % abundance of CFTR was normalized firstly to calnexin loading and then to DMSO control.
protein, thus suggesting that assembly of CFTR can be partially
restored through structural changes at relevant interfaces even in
the absence of residue F508 (Pedemonte et al., 2005; Mendoza
et al., 2012; Molinski et al., 2012).
To assess the effect of TMA analogs on the F508del-
CFTR protein, which was already stabilized by a second-
site mutation at the NBD1-ICL4 interface, we expressed
F508del/R1070W in HEK-293 cells and studied the effect of
TMA analogs on F508del/R1070W-dependent chloride eﬄux.
In agreement with previous data (Okiyoneda et al., 2013),
lumacaftor significantly enhanced F508del/R1070W-dependent
chloride eﬄux and protein expression (Figures 7A,C), whilst
both TMA and its analogs were ineffective (Figures 7B,D).
DISCUSSION
A large number of pharmacological modulators have been
identified, which can rescue the expression and/or function of
the mutated CFTR protein. The potentiator ivacaftor alone,
or in combination with the corrector lumacaftor, are the
only pharmacological modulators of CFTR currently approved
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FIGURE 7 | TMA and its analogs failed to have an additive effect with the second-site mutation R1070W. (A) Functional measurements, using membrane
depolarization dye assay, of F508del/R1070W-CFTR. HEK293 cells were transiently transfected with F508del/R1070W-CFTR mutant and treated for 24 h with:
DMSO, lumacaftor (3 µM), TMA (200 nM), DMA (200 nM), ALLO (200 nM), IPEMA (200 nM), and IPDMA (200 nM). Following 5 min baseline measurements, CFTR
was activated by FSK (10 µM). After 5 min incubation, ivacaftor (1 µM) was acutely added, and after 10 min, the CFTR inhibitor (CFTRinh-172, 10 µM) was added to
deactivate CFTR. (B) Bar graph represents the mean (±SEM) of maximum chloride efflux rates after CFTR activation of three experiments. Statistical comparisons
were made using one-way ANOVA test (∗∗∗∗P < 0.0001). (C) HEK293 cells were transiently transfected with the F508del/R1070W-CFTR mutant and treated for
24 h at 37◦C with DMSO, lumacaftor (3 µM), TMA (200 nM), DMA (200 nM), ALLO (200 nM), IPEMA (200 nM), and IPDMA (200 nM). C: mature,
complex-glycosylated CFTR; B: immature, core-glycosylated CFTR. (D) Bars represent the mean (±SEM) of the ratio of CFTR bands [C/(C+B)] of three experiments.
Statistical comparisons were made using one-way ANOVA test (∗∗∗∗P < 0.0001).
for treatment of CF. Nevertheless, lumacaftor therapy in
combination with ivacaftor does not seem to provide a significant
improvement in the lung function of F508del homozygous
patients. It has also recently been reported that long-term
ivacaftor treatment enhances the turnover of rescued F508del-
CFTR at the cell surface, and induces a significant decrease of
cell surface stability (Cholon et al., 2014; Veit et al., 2014), thus
suggesting that identification of alternative dual-acting CFTR
modulators may be a valuable perspective. Dual-acting small-
molecules have been recently identified, which independently
promote F508del-CFTR trafficking to the plasma membrane and
boost its channel activity (Pedemonte et al., 2011; Phuan et al.,
2011; Liu et al., 2018).
In the present study, we describe dual acting TMA analogs
which are effective in both correcting F508del-CFTR and
potentiating CFTR-dependent chloride transport. This evidence
supports previous data obtained using TMA (Favia et al.,
2014), thus indicating that structural modifications of TMA
scaffold maintain its ability to modulate CFTR activity. More
specifically, the insertion of more hindered substituents at the
fourth position of the angelicin scaffold, as IPEMA, preserves the
CFTR correction and potentiation properties of this compound,
and allows for the prevention of unwanted photoreactivity and
mutagenicity, which characterized the parent TMA molecule.
Interestingly, IPEMA is the most effective potentiator and the
most potent corrector among these TMA analogs, which makes
it a promising agent for the treatment of CF. TMA exhibits
independent corrector and potentiator activities, similar to those
of lumacaftor and ivacaftor. Like lumacaftor, it also interacts
directly with MSD1 of CFTR (Laselva et al., 2016). Our data
demonstrates that these independent corrector and potentiator
activities are preserved in the structurally related TMA analogs.
In FRT cells, 100 nM TMA induced an increase of CFTR
activity similar to that produced by 5 mM lumacaftor, supporting
data previously reported (Favia et al., 2014) (Figures 2B, 3).
Although TMA analogs herein described are very potent F508del
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CFTR correctors, their efficacy seems to be lower than that of
TMA or lumacaftor (Figures 2B, 3).
Rescue of F508del-CFTR function by TMA analogs IPEMA,
IPDMA, DMA, ALLO was observed in FRT and HEK-293
cells, and also in human bronchial epithelial cells CuFi-1 and
CFBE41o-F508del. This indicates that the corrector effect is not
dependent on cell background and that these analogs also share
similar mechanisms as TMA, since simultaneous addition of
TMA and its analogs fails to elicit an additive effect on the
F508del-CFTR processing defect.
Similar to lumacaftor and TMA, functional rescue of F508del-
CFTR by TMA analogs was accompanied by a significant
increase of the fully glycosylated mature Band C, representing
F508del-CFTR protein which as trafficked from the ER
to Golgi and plasma membrane. When we compared the
efficacy of TMA analogs with that observed for lumacaftor
or TMA, the steady state levels of the mature Band C were
found to be very similar. Interestingly, both TMA and its
structurally related analogs exhibit greater potency in enhancing
steady state abundance of Band C compared to lumacaftor.
Notably, two TMA analogs, IPEMA and IPDMA, considerably
increased immature Band B expression of F508del-CFTR, thus
suggesting that these compounds may increase the stability of
the F508del-CFTR immature form, at an early phase of its
biogenesis.
In the present study, we hence demonstrate that TMA and its
analogs rescue F508del-CFTR by stabilization of the NBD1/ICL4
interface. Using the R1070W second-site/suppressor mutation,
which enhances stability of the NBD1/ICL4 interdomain
interface, in the context of F508del, we also observed that TMA
and its analogs failed to show an additional effect on relative
abundance of Band C. These findings are contradictory to those
of lumacaftor, for which additional correction of the processing
defect was observed in the context of the double mutant.
Therefore, lumacaftor corrects F508del-CFTR by modifying
multiple intramolecular interactions in addition to F508del-
NBD1 and ICL4.
The TMA analogs described in this study exhibited several
advantages which would make them promising therapeutic
agents in CF. They were found to be dual correctors and
potentiators, acting through binding to the MSD1 domain
of CFTR, stabilizing the interface between NBD1 and
ICL4, facilitating correct folding and ultimately preventing
premature degradation. According to previous evidence of
anti-inflammatory properties exerted through inhibition of
NF-κB/DNA interactions, along with lower risk of side effects
compared to the parent TMA, some TMA analogs such as
DMA, ALLO, and IPEMA should hence be further investigated
in view of their possible role for treating CF. Therefore, these
TMA analogs may be seen as a promising therapeutic option for
CF disease due to the absence or minimized mutagenicity and
photo-reactivity potential.
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